Abstract

The most pressing need of many investigators in the MAMDC consortium is a reliable, rapid and relatively inexpensive source of synthetic peptides (or protein fragments) which are not commercially available. Currently, 13 MAMDC investigators are engaged in 23 funded projects that have this requirement. The long waits and high costs of the current UCLA Peptide Facility have frustrated all of us. more importantly, they have caused considerable delays in our research progress. Therefore, we are proposing a peptide synthesis and purification core that will a) make large numbers of closely related peptides in small quantities by the Geysen pin method, and b) make up to 200 mg quantities of smaller numbers of peptides by the Houghton method. This facility will synthesize peptides on a scale and to a degree of purity fitted to their use. Consultation and equipment will be provided for preparation of protein fragments and for efficient chromatographic purification of proteins.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR036834-09
Application #
3728040
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095

  Publications

Jawaheer, Damini; Maranian, Paul; Park, Grace et al. (2010) Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 37:2475-85
Ranganath, Veena K; Yoon, Jeonglim; Khanna, Dinesh et al. (2007) Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 66:1633-40
Kahn, Katherine L; MacLean, Catherine H; Liu, Honghu et al. (2007) The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care. Med Care 45:55-65
Kahn, K L; Maclean, C H; Wong, A L et al. (2007) Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum 57:707-15
Kahn, K L; MacLean, C H; Liu, H et al. (2006) Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. Arthritis Rheum 55:884-91
Liu, Honghu; Harker, Judith O; Wong, Andrew L et al. (2004) Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis. Semin Arthritis Rheum 33:302-10
Riemekasten, Gabriela; Langnickel, Dirk; Enghard, Philipp et al. (2004) Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 173:5835-42
La Cava, Antonio; Ebling, Fanny M; Hahn, Bevra H (2004) Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 173:3542-8
Amjadi-Begvand, Sogol; Khanna, Dinesh; Park, Grace S et al. (2004) Dating the ""window of therapeutic opportunity"" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol 31:1686-92
Wong, Andrew L; Harker, Judith O; Mittman, Brian S et al. (2004) Development and evaluation of a patient self-report case-finding method for rheumatoid arthritis. Semin Arthritis Rheum 34:484-99

Showing the most recent 10 out of 111 publications